GBIO Generation Bio

Generation Bio Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

Generation Bio Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., July 07, 2025 (GLOBE NEWSWIRE) -- (Nasdaq:GBIO), a biotechnology company working to change what’s possible for people living with T cell-driven autoimmune diseases, today announced that, on July 1, 2025, the company granted equity awards to one new employee, pursuant to the company’s 2025 Inducement Stock Incentive Plan, as an inducement material to such new employee’s entering into employment with the company in accordance with Nasdaq Listing Rule 5635(c)(4).

The employee received non-statutory stock options stock options to purchase an aggregate of 128,600 shares of the company’s common stock. The options have an exercise price of $0.32 per share, which is equal to the closing price of the company’s common stock on the date of grant. The options have a 10-year term and will vest over a period of four years, with 25% of the shares vesting on the first anniversary of the employee’s start date and 6.25% of the shares underlying the option vesting quarterly thereafter, subject to the employee’s continued service with the company through the vesting dates. The inducement grant is subject to the terms and conditions of award agreements and the company’s 2025 Inducement Stock Incentive Plan.

About Generation Bio   

Generation Bio is a biotechnology company working to change what’s possible for people living with T cell-driven autoimmune diseases. The company is developing redosable therapeutics that reprogram T cells in vivo to reduce or eliminate the production and persistence of autoreactive T cells, which erroneously recognize and attack the body’s own tissues, causing autoimmune diseases. Generation Bio’s innovative approach leverages cell-targeted lipid nanoparticles (ctLNP) to selectively deliver small interfering RNA (siRNA) to T cells. This combination of selective delivery and an intracellular, genetically precise mechanism of target engagement could unlock a series of high-value, historically undruggable disease-driving genes in autoimmunity.

For more information, please visit .

Investors and Media Contact  

Maren Killackey  

Generation Bio  

  

857-371-4638



EN
07/07/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Generation Bio

 PRESS RELEASE

Generation Bio Announces Inducement Grant under Nasdaq Listing Rule 56...

Generation Bio Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4) CAMBRIDGE, Mass., July 07, 2025 (GLOBE NEWSWIRE) -- (Nasdaq:GBIO), a biotechnology company working to change what’s possible for people living with T cell-driven autoimmune diseases, today announced that, on July 1, 2025, the company granted equity awards to one new employee, pursuant to the company’s 2025 Inducement Stock Incentive Plan, as an inducement material to such new employee’s entering into employment with the company in accordance with Nasdaq Listing Rule 5635(c)(4). The employee received non-statu...

 PRESS RELEASE

Generation Bio to Present at the 2025 Jefferies Global Healthcare Conf...

Generation Bio to Present at the 2025 Jefferies Global Healthcare Conference CAMBRIDGE, Mass., May 28, 2025 (GLOBE NEWSWIRE) -- (Nasdaq:GBIO), a biotechnology company working to change what’s possible for people living with T cell-driven autoimmune diseases, announced that Geoff McDonough, M.D., president and chief executive officer, will present at the Jefferies Global Healthcare Conference on Wednesday, June 4th at 8:10 a.m. ET. A live webcast of the presentation will be available on the investor section of the company’s website at . A replay will be available there for 30 days follow...

Wedbush Research
  • Wedbush Research
 PRESS RELEASE

Generation Bio Reports Recent Business Highlights and First Quarter 20...

Generation Bio Reports Recent Business Highlights and First Quarter 2025 Financial Results -  Company continues to advance its strategy to develop first-in-class treatments for T cell-driven autoimmune diseases using its cell-targeted lipid nanoparticle (ctLNP) technology to deliver siRNA -  Lead target and portfolio strategy to be announced mid-2025 -  Cash balance of $157.6 million expected to fund operations into 2H 2027 CAMBRIDGE, MASS., May 07, 2025 (GLOBE NEWSWIRE) -- . (Nasdaq: GBIO), a biotechnology company working to change what’s possible for people living with T cell-d...

David Nierengarten ... (+3)
  • David Nierengarten
  • Dennis Pak
  • Martin Fan

ResearchPool Subscriptions

Get the most out of your insights

Get in touch